Performance of HALO Halozyme Therapeutics | 54.4% in 12m
Compare HALO with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Halozyme Therapeutics with its related Sector/Index XBI
Performance Duell HALO vs XBI
| TimeFrame | HALO | XBI |
|---|---|---|
| 1 Week | -0.84% | 1.00% |
| 1 Month | 7.97% | 3.39% |
| 3 Months | 21.9% | 5.72% |
| 6 Months | 44.3% | 3.10% |
| 12 Months | 54.4% | 28.65% |
| YTD | 61.9% | 9.92% |
| Rel. Perf. 1m | 0.49 | |
| Rel. Perf. 3m | 2.90 | |
| Rel. Perf. 6m | 3.36 | |
| Rel. Perf. 12m | 3.36 | |
| Spearman 1m | -0.12 | -0.17 |
| Spearman 3m | 0.90 | 0.62 |
Is Halozyme Therapeutics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Halozyme Therapeutics (NASDAQ:HALO) is currently (September 2024)
a good stock to buy. It has a ValueRay Fundamental Rating of 89.59 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HALO as of September 2024 is 69.48. This means that HALO is currently undervalued and has a potential upside of +11.52% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HALO as of September 2024 is 69.48. This means that HALO is currently undervalued and has a potential upside of +11.52% (Margin of Safety).
Is HALO a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
Values above 0%: HALO is performing better - Values below 0%: HALO is underperforming
Compare HALO with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -2.56% | 3.13% | 35.44% | 26.95% |
| US NASDAQ 100 | QQQ | -3.48% | 3.13% | 37.34% | 25.86% |
| US Dow Jones Industrial 30 | DIA | -1.70% | 3.26% | 38.05% | 33.56% |
| German DAX 40 | DBXD | -0.47% | 3.51% | 41.61% | 36.09% |
| UK FTSE 100 | ISFU | -0.05% | 4.81% | 33.44% | 36.73% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 1.00% | 12.48% | 53.01% | 65.90% |
| Hongkong Hang Seng | HSI | -0.40% | 4.79% | 47.44% | 59.28% |
| Japan Nikkei 225 | EXX7 | -1.99% | 2.00% | 47.48% | 40.58% |
| India NIFTY 50 | INDA | -1.75% | 4.22% | 32.57% | 26.35% |
| Brasil Bovespa | EWZ | 1.40% | 8.48% | 51.39% | 57.28% |
HALO Halozyme Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -1.40% | 6.29% | 36.37% | 25.59% |
| Consumer Discretionary | XLY | -3.00% | -2.13% | 38.44% | 42.19% |
| Consumer Staples | XLP | -1.06% | 2.14% | 32.95% | 35.27% |
| Energy | XLE | 1.44% | 13.25% | 47.07% | 58.76% |
| Financial | XLF | 0.43% | 2.75% | 34.86% | 24.75% |
| Health Care | XLV | -1.72% | 3.67% | 37.52% | 34.56% |
| Industrial | XLI | -2.48% | 3.43% | 37.85% | 29.26% |
| Materials | XLB | -1.74% | 3.78% | 41.79% | 39.65% |
| Real Estate | XLRE | -3.73% | -0.04% | 29.80% | 27.95% |
| Technology | XLK | -5.61% | 2.17% | 40.01% | 23.49% |
| Utilities | XLU | -1.90% | 2.94% | 20.25% | 31.01% |
| Aerospace & Defense | XAR | -1.95% | 4.15% | 34.27% | 23.00% |
| Biotech | XBI | -1.84% | 4.58% | 41.21% | 25.71% |
| Homebuilder | XHB | -4.05% | -0.02% | 34.08% | 6.61% |
| Retail | XRT | -0.34% | 7.05% | 46.30% | 34.71% |
Does Halozyme Therapeutics outperform its market, is HALO a Sector Leader?
Yes, over the last 12 months Halozyme Therapeutics (HALO) made 54.36%, while its related Sector, the SPDR S&P Biotech (XBI) made 28.65%.
Over the last 3 months HALO made 21.91%, while XBI made 5.72%.
Yes, over the last 12 months Halozyme Therapeutics (HALO) made 54.36%, while its related Sector, the SPDR S&P Biotech (XBI) made 28.65%.
Over the last 3 months HALO made 21.91%, while XBI made 5.72%.
| Period | HALO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 7.97% | 3.39% | 4.84% |
| 3 Months | 21.91% | 5.72% | 3.61% |
| 12 Months | 54.36% | 28.65% | 27.41% |